Corvus Pharmaceuticals, Inc. (CRVS) vs Monte Rosa Therapeutics, Inc. (GLUE)

Corvus Pharmaceuticals, Inc. and Monte Rosa Therapeutics, Inc. are both Biotechnology companies. Corvus Pharmaceuticals, Inc. and Monte Rosa Therapeutics, Inc. are of similar size ($999.9M and $992.6M). Corvus Pharmaceuticals, Inc. has the higher net margin (0.00% vs −560.9%) and the lower return on invested capital (−352.5% vs 0.00%). Across the 13 metrics below, Corvus Pharmaceuticals, Inc. leads on 9 and Monte Rosa Therapeutics, Inc. on 4.

Valuation

Metric CRVS GLUE Biotechnology median
P/E n/m n/m 7.88
P/S n/m 41.58 11.47
P/B 4.76 2.45 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 19.96 10.73
Earnings yield (5.25%) (14.95%) (28.84%)
Free cash flow yield (4.21%) (2.69%) (23.03%)

Profitability

Metric CRVS GLUE Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (633.04%) 0.00%
Net margin 0.00% (560.85%) 0.00%
Free cash flow margin 0.00% (111.66%) 0.00%
Return on equity (18.98%) (42.66%) (57.72%)
Return on assets (17.64%) (30.67%) (49.22%)
Return on invested capital (352.49%) 0.00% 0.00%

Growth

Metric CRVS GLUE Biotechnology median
Revenue growth (TTM) — (83.86%) 5.64%
EPS growth (last fiscal year) 81.21% 53.06% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRVS GLUE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.16 10.58 4.73
Net debt to EBITDA 1.28 8.22 0.96

Dividend

Metric CRVS GLUE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CRVS GLUE Biotechnology median
Market cap 992.63m 999.87m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack